Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide ...

In a report released today, Thomas Wakim from Bell Potter maintained a Buy rating on Neuren Pharmaceuticals ... Uncover insightful assessments of a stock's market performance and potential with ...

Jefferies analyst David Stanton maintained a Buy rating on Neuren Pharmaceuticals Limited (NURPF – Research Report) today and set a price target of A$27.40. The company’s shares closed last ...

The analysts covering Neuren Pharmaceuticals Limited (ASX ... imply the business will grow sales slower than the wider market. We're also surprised to see that the price target went unchanged.